STAT3 is activated by JAK1–2, and the JAK1–2 inhibitor ruxolitinib has been approved by the FDA for the treatment of myelofibrosis and polycythemia vera, and is currently being tested in pancreatic and breast cancer clinical trials. The gene discussed is STAT3; the disease is acquired polycythemia vera.